STOCK TITAN

Bone Biologics (NASDAQ: BBLG) delays 2026 meeting to September 28

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Bone Biologics Corporation postponed its 2026 annual meeting of stockholders, originally set for August 11, 2026, to September 28, 2026 at 11:30 a.m. Eastern Time at its Burlington, Massachusetts offices.

The Board plans to file a Definitive Proxy Statement on Schedule 14A including an additional proposal and concluded more time is needed for stockholders to review materials. The new record date is August 6, 2026, and the deadline for stockholder nominations or other business is July 26, 2026.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Rescheduled annual meeting date September 28, 2026 Date of Bone Biologics Corporation 2026 annual meeting of stockholders
Original annual meeting date August 11, 2026 Prior scheduled date for the 2026 annual meeting before postponement
Meeting time 11:30 a.m. Eastern Time Time of the rescheduled 2026 annual meeting on September 28, 2026
Record date August 6, 2026 Record date for stockholders entitled to vote at the 2026 annual meeting
Proposal and nomination deadline July 26, 2026 Deadline for stockholder submissions of director nominees or other business
Definitive Proxy Statement regulatory
"The company intends to file a Definitive Proxy Statement on Schedule 14A"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
Schedule 14A regulatory
"Intends to file a Definitive Proxy Statement on Schedule 14A with the SEC"
Schedule 14A is a document that companies file with regulators to share important information with shareholders before a big vote, like approving a merger or election of directors. It matters because it helps investors understand what’s happening so they can make informed decisions about the company’s future.
record date regulatory
"The new record date for the Annual Meeting will be August 6, 2026"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
annual meeting of stockholders regulatory
"Postpone the 2026 annual meeting of stockholders previously scheduled for August 11, 2026"
Board of Directors regulatory
"On July 15, 2026, the Board of Directors of Bone Biologics Corporation"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

When will Bone Biologics (BBLG) hold its rescheduled 2026 annual meeting?

Bone Biologics will hold its 2026 annual meeting on September 28, 2026, at 11:30 a.m. Eastern Time. The meeting will take place at the company’s offices, 2 Burlington Woods Drive, Ste. 100, Burlington, MA 01803.

Why did Bone Biologics (BBLG) postpone its 2026 annual meeting?

The Board postponed the meeting to allow time to file a Definitive Proxy Statement on Schedule 14A that includes an additional proposal and to provide stockholders more time to review and consider the proxy materials before voting.

What is the new record date for Bone Biologics (BBLG) 2026 annual meeting?

The new record date for the 2026 annual meeting is August 6, 2026. Stockholders of record as of that date will be entitled to receive notice of and vote at the rescheduled annual meeting on September 28, 2026.

What is the deadline for Bone Biologics (BBLG) stockholder proposals or director nominations?

The deadline for stockholder submissions of director nominees or other business for the 2026 annual meeting is July 26, 2026, which is ten calendar days following the date of the company’s current report about the postponement.

Where will Bone Biologics (BBLG) hold its 2026 annual meeting?

The 2026 annual meeting will be held at Bone Biologics’ offices at 2 Burlington Woods Drive, Ste. 100, Burlington, MA 01803. The meeting is scheduled for 11:30 a.m. Eastern Time on September 28, 2026.
false 0001419554 0001419554 2026-07-15 2026-07-15 0001419554 BBLG:CommonStockParValue0.001PerShareMember 2026-07-15 2026-07-15 0001419554 BBLG:WarrantsToPurchaseCommonStockParValue0.001PerShareMember 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 15, 2026

 

 

 

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40899   42-1743430

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2 Burlington Woods Drive, Ste. 100

Burlington, MA

  01803
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 552-4452

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BBLG   Nasdaq Capital Market
         
Warrants to Purchase Common Stock, par value $0.001 per share   BBLGW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01 Other Events.

 

On July 15, 2026, the Board of Directors (the “Board”) of Bone Biologics Corporation (the “Company”) determined to postpone the 2026 annual meeting of stockholders (the “Annual Meeting”), which was previously scheduled to be held on August 11, 2026. The Company intends to file a Definitive Proxy Statement on Schedule 14A with the Securities and Exchange Commission that includes an additional proposal to be voted on by stockholders and the Board determined additional time was necessary for stockholders to consider the proxy materials. The Annual Meeting will be held at the Company’s offices, 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803, on September 28, 2026 at 11:30 a.m. Eastern Time and the new record date for the Annual Meeting will be August 6, 2026. In connection with the postponement, the deadline for stockholder submissions of director nominees or proposals to bring other business before the Annual Meeting is now ten calendar days following the date of this Current Report on Form 8-K, or July 26, 2026.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    BONE BIOLOGICS CORPORATION
   
Date: July 16, 2026    
  By: /s/ Jeffrey Frelick
    Jeffrey Frelick
    Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

4 documents